Mylan defeats Sanofi’s claims it illegally prevented competition to EpiPen
Sanofi-Aventis failed to demonstrate that Mylan monopolised the market for epinephrine auto-injectors used to treat severe allergic reactions, a Kansas federal court ruled in a recently unsealed opinion.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10